CTLT Catalent
- 55.890
- -0.060-0.11%
Catalent News
Express News | NYSE Order Imbalance 158865.0 Shares on Sell Side
Goldman's Debt Issuers Stocks Basket
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S (NYSE:NVO) after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and d
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48.
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Express News | NYSE Order Imbalance 78033.0 Shares on Buy Side
Top 10 Best Performing S&P 500 Health Care Stocks of 2024
Novo Nordisk Parent Resubmits Application Seeking US Antirust Nod for Catalent Deal
Novo Nordisk (NOVO-B.CO) parent Novo Nordisk Foundation filed a new application to secure the US Federal Trade Commission's approval on its proposed acquisition of manufacturing subcontractor Catalent
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down about 0.2% The iShares Biotechnology ETF (IBB) rose 0.
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Health care stocks were flat to higher premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. Alnylam Pharmaceuticals (ALNY) was
Novo Nordisk Parent Refiles US Application on Catalent Deal
Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
In the preceding three months, 6 analysts have released ratings for Catalent (NYSE:CTLT), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates their recent
Catalent Price Target Maintained With a $63.50/Share by Stephens & Co.
Catalent Price Target Maintained With a $63.50/Share by Stephens & Co.
Express News | Stephens & Co. Reiterates Equal-Weight on Catalent, Maintains $63.5 Price Target
Catalent Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 12.13% Stephens & Co. → $63.5 Reiterates Equal-Weight → Equal-Weight 02/20/2024 12.13% RBC Capi
Express News | Invenra To Collaborate With Catalent To Co-Discover Novel Bispecific ADCs
Invenra Inc. Announces a Strategic Collaboration With Catalent to Co-Discover Novel Bispecific ADCs
Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in
Aseptic Fill Finish Market Trends, Forecast and Competitive Analysis to 2030, Featuring AbbVie, Asymchem, Aenova, APL, BioPharma Solutions, BioReliance, Boehringer Ingelheim and Catalent Biologics
Analysis
Price Target
No Data
